Results 161 to 170 of about 52,225 (202)
Leukemia, 2013 Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies.
K Battmer +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Model Mice for BCR/ABL-Positive Leukemias
Blood Cells, Molecules, and Diseases, 2001p210bcr/abl is detected in almost all chronic myelogenous leukemia (CML) patients and a significant number of acute lymphoblastic leukemia (ALL) cases. It is generated by a reciprocal chromosomal translocation, t(9;22) (q34;q11), and the enhanced kinase activity of the protein is believed to be implicated in the pathogenesis of the diseases. To examine
H, Honda, H, Hirai
openaire +2 more sources
Current and future management of Ph/BCR-ABL positive ALL
Expert Review of Anticancer Therapy, 2014Following the introduction of targeted therapy with tyrosine kinase inhibitors (TKI) at the beginning of the past decade, the outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has dramatically improved. Presently, the use of refined programs with first/second generation TKI's and chemotherapy together with
Elena, Maino +6 more
openaire +2 more sources
Mechanisms of resistance to imatinib mesylate in Bcr-Abl–positive leukemias
Current Opinion in Oncology, 2002The constitutive activity of the Bcr-Abl tyrosine kinase plays a critical role in the molecular pathogenesis of not only the chronic but also the accelerated and blastic phases of chronic myelogenous leukemia. Therefore, Bcr-Abl tyrosine kinase is a rational therapeutic target in all phases of chronic myelogenous leukemia.
Ramadevi, Nimmanapalli, Kapil, Bhalla
openaire +2 more sources
Management of Bcr–Abl-positive leukemias with dasatinib
Expert Review of Anticancer Therapy, 2007Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia following imatinib failure. Clinical trials have demonstrated its activity across all phases of CML. Dasatinib was superior to high-dose imatinib in a randomized,
openaire +2 more sources
Nuclear positioning of the BACH2 gene in BCR‐ABL positive leukemic cells
Genes, Chromosomes and Cancer, 2006AbstractBACH2 is a B‐cell‐specific transcription repressor and is also know as a tumor suppressor in B cell malignancy. Expression of BACH2 is induced in BCR‐ABL positive lymphoid cell lines including BV173 by imatinib, a molecular targeting agent for the treatment of chronic myeloid leukemia (CML).
Atsushi, Ono +9 more
openaire +2 more sources
Function of STAT5 Isoforms in Bcr-Abl Positive Cells
Blood, 2011Abstract Abstract 1313 Chronic myeloid leukemia (CML) is caused by expression of the BCR-ABL oncogene product which exerts constitutive tyrosine kinase activity. Specific inhibition of the BCR-ABL tyrosine kinase activity by small tyrosine kinase inhibitors (TKIs) is now well established as initial therapy for newly ...
Michael Schaller-Schoenitz +4 more
openaire +1 more source
Jumping translocation of 1q in a BCR/ABL-positive acute lymphoblastic leukemia
Cancer Genetics and Cytogenetics, 2005Jumping translocations (JT) are rare chromosomal abnormalities in which an identical copy of a chromosomal region (donor) is translocated to a different chromosome (acceptor). Chromosome 1 is often involved as donor chromosome. JTs of the long arm of chromosome 1 (1q) or parts of it are associated with a poor outcome.
Antje-Friederike, Pelz +2 more
openaire +2 more sources